"Pain is inevitable.....suffering is optional"

Wasek Faisal MBBS, MPhil, FRACP, FRCP(Edin)

Medical Oncologist, BRICC, Grampians Health
Clinical Director, Grampians Integrated Cancer Services
Senior Visiting Research Fellow, La Trobe University, Melbourne







Disclosures

- Advisory Board: Roche, BMS, Astra Zeneca
- Travel: BMS, Roche
- Speaker Honorarium: MSD, BMS, Astra Zeneca
- Research Funding: Astra Zeneca, MRFF, Victorian Cancer Agency, TOGA

How far we have come.....





Fig 1. Overall survival in relation to treatment. Intent-to-treat analysis, n=334. Log-rank P=.0205. Median survival was 8.6 months (95% CI, 7.3 to 9.9 months) for gemcitabine and 10.0 months (95% CI, 8.0 to 12.0 months) for gemcitabine plus carboplatin. Hazard ratio =0.767 (95% CI, 0.612 to 0.960).



JCO (2023). 41:1992-1998

JCO (2005). 23(33): 8380-8388

Palliative care used to be easy (I think)....





Fig 1. Overall survival in relation to treatment. Intent-to-treat analysis, n = 334. Log-rank P = .0205. Median survival was 8.6 months (95% CI, 7.3 to 9.9 months) for gemcitabine and 10.0 months (95% CI, 8.0 to 12.0 months) for gemcitabine plus carboplatin. Hazard ratio = 0.767 (95% CI, 0.612 to 0.960).

JCO (2005). 23(33): 8380-8388

With great advances, comes greater challenges.....




Challenges.....points to ponder

- Early referral.....how early is too early?
- Pseudo-progression vs hyper-progression......how do you know?
- Going well......discharge from Pall Care?
- Going well......stay with Pall Care.....how long for?
- Prognostication.....it is a science or an art?
- VAD request.....what if?


Advances in Oncology

- Diagnostic:
 - Liquid Biopsy
- Therapeutic
 - Chemotherapy
 - Immunotherapy
 - Newer generation of immunotherapy
 - Targeted therapy
 - ADC
 - Tumour vaccines
 - Theranostics
 - Any combination of above
- Supportive


Liquid Biopsy




Immunotherapy in cancer



Tumour Vaccines



Theranostics in cancer



Antibody-Drug Conjugates (ADC)

Antibody-Drug Conjugate Mechanism of Action Targeted drug delivery B) Pro-survival Apoptosis receptor Cancer cell blockade 🖠 Antibody-dependent cellular cytotoxicity Effector cell

Advances in Supportive Care in Oncology

- Analgesics, Anti-emetics, Aperients, etc.
- Innovative models of supportive care delivery
- Medicinal cannabis
- Survivorship care
- Greater patient autonomy
- Rise of the Social Media.....help or hindrance?

Toxicities of interest.....old is new again.

- A case from 2013.....long before immunotherapy was routine
 - 65F with metastatic vulval SqCC with nodal mets, chronic leg lymphoedema
 - Surgery, Pall RT & chemo, on watch & wait, ECOG 1
 - Co-morbidities: GORD, IBS, Hypothyroid, OA
 - 3x hospital admissions with leg pain
 - 1st admission Opiate rotation from Fentanyl to MS Contin, and commenced on Gabapentin
 - 2nd admission: Left leg extensive DVT, commenced on LMWH
 - Current admission: Ongoing L-leg pain with suboptimal pain control

Case....continued

- On admission:
 - MS Contin increased from 60mg BD to 90mg BD, Gabapentin increased from 100mg TDS to 300mg TDS.
 - Concomitant UTI: MSU >100 WBC, Enterococcus and enteric Gm neg Rods. Given stat dose Gentamycin 300mg & Flucloxacillin 2g IV.
 Commenced on PO Cephalexin 500mg QID
 - ARF: eGFR 45 (base line >75), pre-renal

- Admission Day 4:
 - pain well controlled, but new onset delirium and visual hallucinations.
 - Gabapentin dose reduced to 100mg TDS
 - PRN Benzodiazepins for delirium

- Admission Day 5:
 - Worsening delirium, febrile
 - Blood cultures Neg, CXR- NAD, CRP 421
 - Gabapentin stopped, MS Contin reduced to 60mg

- Over Christmas/New Year holiday period:
 - Deteriorating, with increasing drowsiness, unable to take oral meds, increasing confusional state - ?terminal delirium
 - Oral meds ceased
 - Commenced on SCIP with Fentanyl 750mcg, Midazolam 7.5mg, Haloperidol 2mg
 - Agitation, myoclonus: changed to Sufentanyl 125mcg, Midazolam 15mg, Haloperidol 2.5mg
 - Increasing agitation: Sufentanyl increased to 150mcg, Midazolam 20mg and changed to Levomepromazine 25mg.

- Admission Day-9:
 - GCS 4/15, Hypothermic (35.2), Clinically dehydrated
 - SCIP changed to Hydromorphone 9mg, with Levo reduced to 12.5mg and Midazolam to 15mg.
 - 1L SC fluid given overnight.
 - IM Ceftriaxone commenced

- Admission Day-10:
 - Hx and progress reviewed.
 - Clinical deterioration not fully explained by cancer burden.
 - O/E: GCS 5/15, Deep tendon reflexes absent
 - Urgent TSH 11.67, free T4 17
 - FBC, U&Es, LFTs, CMP, random Cortisol all normal. CRP 121

Working Hypothesis

- Clinical deterioration
 - precipitated by Sepsis (UTI), leading to probable myxedema coma (due to omission of Thyroxine for 5-days, on a background of subclinical hypothyroidism)
 - Contributed by escalating doses of Benzos and antipsychotics.

Management

- Midazolam and Levomepromazine stopped.
- Stat dose Hydrocortisone 200mg IV and commenced on IV Hydrocortisone 100mg QID
- Stat dose IV Thyroxine 20mcg given

Next day...

- GCS 15/15
- Oriented to time, place, person.
- Recommenced on PO Thyroxine, PO ABx, IV cannula removed.

New drugs.....old toxicities.....different expectations

- Hypothyroidism
- Hyperthyroidism
- Pneumonitis
- Colitis
- Drug-induced liver injury/hepatitis
- Any other "...itis" you can think of

Thank you

